比菲德氏菌 BB536 Bifidobacterium longum BB536 × 潰瘍性結腸炎
結論：證據支持但有警示
BB536 × 潰瘍性結腸炎的菌株專屬證據僅有一篇日本小型 RCT（Tamaki 2016, n=56, 8 週），且主要終點臨床緩解率未達顯著差異（63% vs 52%, P=0.
C 🟠 C 薄弱證據 附警語發布 🚨 high — heavy affiliate marketing in TW community
BB536 × 潰瘍性結腸炎的菌株專屬證據僅有一篇日本小型 RCT（Tamaki 2016, n=56, 8 週），且主要終點臨床緩解率未達顯著差異（63% vs 52%, P=0.395），僅次要終點（UCDAI、內視鏡指數、Mayo subscore）顯著改善；缺乏 Cochrane SR 或大型 MA。
重要的是，主流臨床指引（ACG 2025、AGA、Mayo Clinic、Cleveland Clinic、Harvard Health）均不建議常規使用益生菌治療 UC，且皆未在菌株層級背書 BB536。
EFSA 已正式拒絕 BB536 三項物種層級健康聲稱（雖非 UC 適應症）。
整體屬於「弱菌株證據 + 強反向指引立場」的混合狀態，符合 C 等級。
⚖️
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查原始分數 0.44
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
C · 附警語發布
信心度
67%
證據方向大致一致
證據層級
E7
單篇小型隨機對照試驗
▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.439
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial
— 詳細結論請見 PubMed 原文
前往 PubMed
Active hexose-correlated compound and Bifidobacterium longum BB536 exert symbiotic effects in experimental colitis
— 詳細結論請見 PubMed 原文
前往 PubMed
L4a US FDA
支持
GRN No. 877 — Bifidobacterium longum BB536. Intended use: ingredient in term infant formula at a level of 1 x 10^8 CFU per gram of product. FDA closure date: December 26, 2019. FDA letter: 'FDA has no questions' regarding the safety of Bifidobacterium longum BB536 when used as described in the notice. (Earlier GRN 268 covered use in conventional foods/beverages.) 來源↗
L4b EU EFSA
謹慎
Scientific Opinion on the substantiation of health claims related to Bifidobacterium longum BB536 and improvement of bowel regularity (ID 3004), normal resistance to cedar pollen allergens (ID 3006), and decreasing potentially pathogenic gastro-intestinal microorganisms (ID 3005) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. Conclusion: Bifidobacterium longum BB536 does not improve… 來源↗
L4c UK NHS
謹慎
— 本適應症無對應資料
L4d TW TFDA / 衛福部
中性
健康食品查驗登記審查採雙軌制，第一軌為「個案審查」，第二軌為「規格標準審查」，通過審查的產品會給予健康食品(小綠人)標章，第一軌的產品上標有「衛部健食字第A00000號」，第二軌的產品標有「衛部健食規字第000000號」。目前健康食品可以宣稱的保健功效項目共有13項，包括調節血脂、胃腸功能改善、護肝、免疫調節、骨質保健、不易形成體脂肪、抗疲勞、輔助調整過敏體質、調節血糖、延緩衰老、牙齒保健、促進鐵吸收、輔助調節血壓。 來源↗
L4e WHO
中性
— 本適應症無對應資料
L5a NIH Office of Dietary Supplements
中性
— 本適應症無對應資料
L5b Mayo Clinic
謹慎
Evidence on probiotic supplements is mixed, and the American Gastroenterological Association does not recommend probiotic supplements for treating ulcerative colitis in most situations. However, they should be treated like medicine and discussed with your healthcare professional before use. 來源↗
L5c Cleveland Clinic
謹慎
Probiotics are probably not harmful, and if you take one and it makes you feel better then fantastic, keep taking it. They can be expensive, though. And there is definitely not evidence that it's going to make anything better long term. 來源↗
L5d Harvard Health
謹慎
Some studies suggest that certain bacterial strains, such as Bifidobacteria and Lactobacilli, are somewhat effective for ulcerative colitis. But these effects are modest compared to standard therapies, and probiotics have not shown enough benefit to be accepted in medical practice. 來源↗
L5e Specialty Society (condition-mapped)
反對
There is not sufficient evidence for routine use of probiotics, prebiotics, or other alternative therapies as primary induction therapy for patients with mildly to moderately active UC. 來源↗
PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 極高
低中高
📍立場總覽
台灣社群（PTT、Dcard、Mobile01）幾乎沒有針對 BB536 用於潰瘍性結腸炎的具名分享；BB536 在台灣社群多被討論於嬰幼兒過敏預防、便秘、腸道保健等情境，並非 UC 病友主要選用菌株。UC 病友討論多聚焦於藥物（5-ASA、生物製劑）與一般「益生菌」泛稱，非特定菌株。
💬社群實感
資料不足
破解迷思 社群最常見的 3 個誤解
✓
事實將「益生菌」泛稱與特定菌株 BB536 混為一談
✓
事實認為市售優格即可達到 BB536 研究劑量（實際多需專用補充品）
✓
事實誤以為益生菌可取代 5-ASA 等 UC 標準治療藥物
🩹 社群通報的副作用
- 初期脹氣（一般益生菌共通反應，非 BB536 特定）
🏷️ 社群熱議品牌
依論壇被提及頻率，非銷售或品質排序。
- Morinaga 森永 BB536
- 大醫生技 BB536
- 森下仁丹 晶球益生菌
- 樂亦康 (孕婦/兒童族群為主)
⚠️ 列出僅代表「TW 社群討論度高」，不代表本站推薦或背書。本站不販售任何產品、無導購連結。
L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳
在台灣，健康食品可宣稱的保健功效包括「免疫調節」和「胃腸功能改善」等13項，產品所准許宣稱之保健功效取決於個別產品所提出科學驗證之結果。通過審查的產品會獲得健康食品標章，第一軌的產品上標有「衛部健食字第A00000號」。
代表來源 ↗ L10b · TFDA 法定身份 官方認定
Bifidobacterium longum is listed in the 可供食品使用原料彙整一覽表 (Approved Food Ingredient List) under the category of lactic acid bacteria (乳酸菌), and is approved for use as a food ingredient or in food processing.
來源 ↗- 5-ASA (mesalamine)
- VSL#3 益生菌 (輔助維持緩解)
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-ulcerative-colitis-INT-bifidobacterium-longum-bb536-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "比菲德氏菌 BB536能改善潰瘍性結腸炎",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 2,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟠 C 薄弱證據"
}
}